HOME > BUSINESS
BUSINESS
- Torii Aims to Turn Profit in 2022, Forecasting Revenue Drop after Gilead HIV Pact Ends
February 8, 2019
- Torii to Sell Futhan to Nichi-Iko after 43% Off-Patent Price Slash
February 7, 2019
- Goichi Matsuda Named as New President of Torii
February 7, 2019
- Torii Launches Early Retirement Program as Part of Restructuring Plan
February 7, 2019
- Daiichi Sankyo’s Cancer Med Pexidartinib Gets Priority Review in US
February 7, 2019
- Kyowa Kirin Commences Japan PII Study of NHE3 Inhibitor for Hyperphosphatemia
February 7, 2019
- JCR, Teijin Launch Japan PI/PII of Regenerative Medicine Product for Cerebral Infarction
February 7, 2019
- Kyowa Kirin to Delay 100 Billion Yen Profit Goal, Plans 1st Voluntary Redundancy Program
February 6, 2019
- Kyowa Kirin Sales Slip 1.9% in 2018, but Profit Up on One-Off Factors
February 6, 2019
- Kyowa Kirin to Market Hisamitsu’s Transdermal Parkinson’s Drug
February 6, 2019
- Taiho Licenses Novel EGFR-TKI to US Firm Outside Japan
February 6, 2019
- Q3 Earnings Rundown: Eisai, Takeda, Ono, and More
February 5, 2019
- Ichiro Watanabe to Head Up Teijin Pharma
February 5, 2019
- Oropharyngeal Candidiasis Drug Oravi Now Available in Japan
February 4, 2019
- Takeda Drops US Filing for Ninlaro Label Expansion, Plans Resubmission with OS Data
February 4, 2019
- Keytruda Beats Opdivo in Q4 Global Sales including Asia
February 4, 2019
- Sawai and 7 Other Generic Makers Seeking Lyrica Patent Invalidity
February 4, 2019
- Chugai Plays It Safe with New 3-Year Plan on Consecutive Re-Pricing, Eyes 7-9% Annual EPS Growth
February 1, 2019
- Oncolys Plans to Begin Japan PII Study of Oncolytic Virus in 2nd Half of 2019
February 1, 2019
- Chugai Renews Record Earnings in 2018 on New Drugs, Exports
February 1, 2019
ページ
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
